企業を読み込み中
Keep exploring
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$129.2BA+
SYKStryker Corp.$118.9BA+
GEHCGE Healthcare Technologies Inc.$37BA
GKOSGlaukos Corp$14.6BA
PENPenumbra, Inc$12.6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A- GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
どうやって稼いでいるか
- Catheter-delivered aortic valve replacement72%
- Catheter-delivered mitral and tricuspid valve repair and replacement11%
- Surgical heart valve products16%
売上構成比はnine months ended September 30, 2026の推計であり、提出された報告書の数字ではありません。
競合
何を売っているか5
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
さらに2件を表示
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
誰が買っているか3
- Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
- Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
- Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
- 2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
- 3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
- 4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.
うまくいかなくなる可能性
- 1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
- 2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
- 3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.
Edwards Lifesciences Corporationについて
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
- 本社
- Irvine, California, United States
- 設立
- 1958
- 従業員数
- Approximately 16,000 (December 31, 2025, medium)
- 上場市場
- New York Stock Exchange
- 決算期
- December 31
Edwards Lifesciences Corporation 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
